

Novel Thiazolidinone-Azole Hybrids: Design, Synthesis and Antimycobacterial Activity Studies

Barbaros Eroglu^a, Keriman Ozadali-Sari^{a*}, Oya Unsal-Tan^a, Sriram Dharmarajan^b, Perumal Yogeewari^b and Ayla Balkan^a

^aDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey. ^bMedicinal Chemistry & Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology & Science – Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Andhra Pradesh, India.

Abstract

To develop novel antimycobacterial agents, a new series of thiazolidinone-azole hybrids 4a-b, 5a-b and 6-13 were designed and synthesized. Thiazolidin-4-ones (4a-b and 5a-b) were obtained by the reaction of *Schiff* bases and hydrazones (2a-b and 3a-b) with mercaptoacetic acid. 5-Benzylidene derivatives (6-13) were gained by treatment of 5a-b with appropriate benzaldehydes according to *Knoevenagel* condensation. To evaluate their structures ¹H NMR, IR, mass spectrometry and elemental analysis data were used. The target compounds were screened for their antimycobacterial activity against *M. tuberculosis* H37Rv strain using the microplate alamar blue assay method. Among them, 6, 10 and 12 (MIC: 14.27-14.74 μM) were found as most active compounds in the series. It was seen that both phenylamino and benzylidene substitutions on thiazolidin-4-one ring caused an improvement in the antimycobacterial activity.

Keywords: Thiazolidin-4-one; Triazole; Imidazole; Antimycobacterial activity.

Introduction

Tuberculosis (TB) is one of the most common infectious diseases known to man. According to the WHO report in 2012, there were almost 9 million new cases of tuberculosis and 1.4 million tuberculosis deaths (1). The problems with current TB treatment are complex and include: a prolonged standard course regimen of six months, which often result in patient noncompliance; emergency of extremely drug-resistant tuberculosis (XDR-TB) strains; lack of effective drugs against the latent state (2-4). Therefore, there is an urgent need for antitubercular agents with improved properties

such as enhanced activity against MDR strains, reduced toxicity, shortened duration of treatment.

Thiazolidin-4-one is an important scaffold known to be associated with several biological activities. It is known that (-)-2-(5-carboxypentyl) thiazolidin-4-one (actithiazic acid) isolated from the culture broth of a strain of streptomyces has antimycobacterial activity (5). This discovery has prompted researchers to focus on new thiazolidin-4-one derivatives as potential antimycobacterial agents (6-10). On the other hand, it has been extensively reported that many structurally diverse compounds having azole moieties such as imidazole (11-14), triazole (15-17), thiazole (18, 19), oxazole (20), pyrazole (21, 22), isoxazole (23), oxadiazole (24) showed antimycobacterial activity. In recent years, one of the important strategies used in antitubercular

* Corresponding author:

E-mail: kozadali@hacettepe.edu.tr




Figure 1. Synthesis of 4a-b and 5a-b. Reagents and conditions: (i) aniline/phenylhydrazine, CH_3COOH , methanol, reflux; (ii) mercaptoacetic acid, 60 °C.

drug development studies is hybridization of the biologically active structures. Considering this strategy, it was reported to achieve a highly active molecule by hybridization of thiazolidin-4-one ring with various active structures (25).

These facts have led us to study on thiazolidinone-azole hybrid compounds which are expected to show antitubercular activity.

Experimental

Chemistry

Melting points were determined with a Thomas-Hoover Capillary Melting Point Apparatus (Philadelphia, PA, USA) and are uncorrected. ATR-FTIR spectra were obtained using the MIRacle ATR accessory (Pike technologies) in conjunction with a Spectrum BX FTIR spectrometer (Perkin Elmer) and were reported in cm^{-1} . The ^1H NMR (400 MHz) spectra (DMSO-d_6) were recorded on a Varian Mercury 400 FT NMR spectrophotometer (Varian Inc, Palo Alto, CA, USA) using TMS as an internal reference (Chemical shift represented in δ ppm). The ESI-MS spectra were measured on a micromass ZQ-4000 single quadrupole mass spectrometer. Elemental analyses (C, H, N) were performed on Leco CHNS 932 analyzer (USA).

General procedure for the preparation of Schiff bases 2a-b and hydrazones 3a-b

Equimolar amounts of an appropriate benzaldehyde and anilin/phenylhydrazine were refluxed in methanol in presence of acetic acid (1

drop) as a catalytic reagent for 4 h. The solvent was evaporated and the crude mixture was used without any purification in the next step.

General procedure for the preparation of 3-phenyl-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 4a-b and 3-(phenylamino)-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 5a-b

A mixture of Schiff bases or hydrazones 2a-b or 3a-b (1 mmol) and excess of mercaptoacetic acid (1 mL) was heated at 60-80 °C until the reaction was completed. Ethyl acetate (5 mL) was added, the organic layer was washed with saturated NaHCO_3 (3x20 mL), water (1x10 mL), dried with Na_2SO_4 and concentrated to give an oily residue. The oily residue was purified by column chromatography on silica gel using hexane-ethyl acetate as eluent (3:7).

3-phenyl-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 4a

53% yield, mp 176-8 °C. ^1H NMR (DMSO-d_6 , 400 MHz); δ 9.25 (1H; s; triazole), 8.21 (1H; s; triazole), 7.77 (2H; d; Ar- H_3'''' and H_5'''' J : 8.4 Hz), 7.60 (2H; d; Ar- H_2'''' and H_6'''' J : 8.4 Hz), 7.36-7.28 (4H; m; Ar- H_2' , H_3' , H_5' and H_6'), 7.16-7.14 (1H; m; Ar- H_4'), 6.61 (1H; s; thiazol., H_2), 4.08 (1H; dd; thiazol., H_{5a} , J : 1.6 Hz, J : 15.6 Hz), 3.92 (1H; d; thiazol., H_{5b} , J : 15.6 Hz). IR: cm^{-1} 1674 (C=O). ESI-MS (m/z); 345 [$\text{M}+\text{Na}$] $^+$, 323 [$\text{M}+\text{H}$] $^+$. Anal. Calcd. for $\text{C}_{17}\text{H}_{14}\text{N}_4\text{OS}$: C, 63.34; H, 4.38; N, 17.38; S, 9.94. Found: C, 62.28; H,

Table 1. Antimycobacterial activities of 4a-b, 5a-b and 6-13

Compounds	X	R	MIC* (μM)
4a	N	-	77.64
4b	CH	-	155.76

Compounds	X	R	MIC* (μM)
5a	N	-	74.18
5b	CH	-	37.20

6	N	H	14.70
7	N	Br	49.60
8	N	CH ₃	56.94
9	N	Cl	27.17
10	CH	H	14.74
11	CH	Br	49.70
12	CH	CH ₃	14.27
13	CH	Cl	27.23
INH			0.36
Rifampin			0.12
Ethambutol			7.65
Ciprofloxacin			4.71

4.45; N, 17.60; S, 9.62.

3-phenyl-2-[4-(1H-imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 4b

47% yield, mp 75-77 °C. ¹H NMR (DMSO-d₆,

400 MHz); δ 8.22 (1H; s; imidazole), 7.71 (1H; s; imidazole), 7.57-7.52 (4H; m; Ar-H_{2'''}, H_{3'''}, H_{5'''} and H_{6'''}), 7.36-7.28 (4H; m; Ar-H_{2'}, H_{3'}, H_{5'} and H_{6'}), 7.17-7.13 (1H; m; Ar-H_{4'}), 7.07 (1H; s; imidazole), 6.60 (1H; s; thiazol., H₂), 4.07




Figure 2. Synthesis of 6-13. Reagent and condition: (i) appropriate benzaldehyde, KOH, ethanol, reflux.

(1H; dd; thiazol., H_{5a} , J : 1.2 Hz, J : 15.6 Hz), 3.90 (1H; d; thiazol., H_{5b} , J : 15.6 Hz). IR; cm^{-1} 1681 (C=O). ESI-MS (m/z); 344 [M+Na]⁺, 322 [M+H]⁺. Anal. Calcd. for $C_{18}H_{15}N_3OS$: C, 67.27; H, 4.70; N, 13.07; S, 9.98. Found: C, 62.48; H, 4.57; N, 13.43; S, 10.08.

3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 5a

48% yield, mp 228-30 °C (dec.). ¹H NMR (DMSO- d_6 , 400 MHz); δ 9.32 (1H; s; triazole), 8.25 (1H; s; triazole), 8.22 (1H; s; NH), 7.88 (2H; d; Ar- H_3'' and H_5'' , J : 8.4 Hz), 7.60 (2H; d; Ar- H_2'' and H_6'' , J : 8.4 Hz), 7.16 (2H; t; Ar- H_3' and H_5'), 6.75 (1H; t; Ar- H_4'), 6.67 (2H; d; Ar- H_2' and H_6' , J : 7.6 Hz), 5.95 (1H; d; thiazol., H_2 , J : 1.2 Hz), 3.98 (1H; dd; thiazol., H_{5a} , J : 1.6 Hz, J : 15.6 Hz), 3.79 (1H; d; thiazol., H_{5b} , J : 15.6 Hz). IR; cm^{-1} 3220 (NH), 1696 (C=O). ESI-MS (m/z); 360 [M+Na]⁺, 338 [M+H]⁺. Anal. Calcd. for $C_{17}H_{15}N_3OS$: C, 60.52; H, 4.48; N, 20.76; S, 9.50. Found: C, 60.31; H, 4.61; N, 20.54; S, 9.65.

3-(phenylamino)-2-[4-(1H-imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 5b

45% yield, mp 163-4 °C. ¹H NMR (DMSO- d_6 , 400 MHz); δ 8.28 (1H; s; imidazole), 8.22 (1H; s; NH), 7.77 (1H; s; imidazole), 7.66 (2H; d; Ar- H_3'' and H_5'' , J : 8.8 Hz), 7.54 (2H; d; Ar- H_2'' and H_6'' , J : 8.8 Hz), 7.16 (2H; t; Ar- H_3' and H_5'), 7.11 (1H; s; imidazole), 6.75 (1H; t; Ar- H_4'), 6.67 (2H; d; Ar- H_2' and H_6' , J : 8.8 Hz), 5.94 (1H; d; thiazol., H_2 , J : 1.6 Hz), 3.97 (1H; dd; thiazol., H_{5a} , J : 1.6 Hz, J : 15.6 Hz), 3.79 (1H; d; thiazol., H_{5b} , J : 15.6 Hz). IR; cm^{-1} 3170 (NH), 1681 (C=O). ESI-MS (m/z); 359 [M+Na]⁺, 337 [M+H]⁺. Anal. Calcd. for $C_{18}H_{16}N_4OS$: C, 64.27;

H, 4.79; N, 16.65; S, 9.53. Found: C, 64.47; H, 4.58; N, 16.83; S, 9.76.

General procedure for the preparation of 5-benzylidene/substitutedbenzylidene-3-(phenylamino)-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 6-13

A mixture of 3-(phenylamino)-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 5a-b (10 mmol) and 4-nonsubstituted/substitutedbenzaldehyde (10 mmol) was refluxed in 30 mL of ethanol in the presence of potassium hydroxide (15 mmol) for 8 h. The solvent was evaporated under reduced pressure and obtained oily residue was crystallized from appropriate solvent.

5-Benzylidene-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 6

38% yield, mp 156-7 °C. ¹H NMR (DMSO- d_6 , 400 MHz); δ 9.29 (1H; s; triazole), 8.46 (1H; s; NH), 8.22 (1H; s; triazole), 7.88 (2H; d; Ar- H_2'' and H_6'' , J : 8.4 Hz), 7.59 (2H; d; Ar- H_3'' and H_5'' , J : 8.4 Hz), 7.56 (2H; d; Ar- H_3'' and H_5'' , J : 7.2 Hz), 7.51 (1H; s; CH=), 7.46 (2H; d; Ar- H_2'' and H_6'' , J : 8.4 Hz), 7.35 (1H; t; Ar- H_4''), 7.15 (2H; t; Ar- H_3' and H_5'), 6.75 (1H; t; Ar- H_4'), 6.65 (2H; d; Ar- H_2' and H_6' , J : 8.0 Hz), 6.33 (1H; s; CH). IR; cm^{-1} 3266 (NH), 1676 (C=O). ESI-MS (m/z); 448 [M+Na]⁺, 426 [M+H]⁺. Anal. Calcd. for $C_{24}H_{19}N_3OS$: C, 67.74; H, 4.50; N, 16.46; S, 7.53. Found: C, 67.37; H, 4.54; N, 16.05; S, 6.81.

5-(4-Bromobenzylidene)-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 7

57% yield, mp 192-3 °C. ¹H NMR (DMSO-d₆, 400 MHz); δ 9.30 (1H; s; triazole), 8.50 (1H; s; NH), 8.23 (1H; s; triazole), 7.88 (2H; d; Ar-H₂" and H₆", *J*: 8.4 Hz), 7.65 (2H; d; Ar-H₃" and H₅"', *J*: 8.4 Hz), 7.59 (2H; d; Ar-H₃" and H₅"', *J*: 8.4 Hz), 7.51 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.48 (1H; s; CH=), 7.15 (2H; t; Ar-H₃' and H₅''), 6.75 (1H; t; Ar-H₄''), 6.44 (2H; d; Ar-H₂' and H₆'', *J*: 7.6 Hz), 6.35 (1H; s; CH). IR; cm⁻¹ 3266 (NH), 1681 (C=O). ESI-MS (m/z); 544 [M+K+2]⁺, 528 [M+Na+2]⁺. Anal. Calcd. for C₂₄H₁₈BrN₅OS.1 H₂O: C, 55.18; H, 3.86; N, 13.41; S, 6.14. Found: C, 54.84; H, 3.73; N, 13.41; S, 6.64.

5-(4-Methylbenzylidene)-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 8

29% yield, mp 161-2 °C. ¹H NMR (DMSO-d₆, 400 MHz); δ 9.31 (1H; s; triazole), 8.48 (1H; s; NH), 8.24 (1H; s; triazole), 7.89 (2H; d; Ar-H₂" and H₆"', *J*: 7.2 Hz), 7.59 (2H; d; Ar-H₃" and H₅"', *J*: 7.6 Hz), 7.48 (1H; s; CH=), 7.46 (2H; d; Ar-H₃" and H₅"', *J*: 8.4 Hz), 7.28 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.15 (2H; t; Ar-H₃' and H₅''), 6.76 (1H; t; H₄''), 6.66 (2H; d; Ar-H₂' and H₆'', *J*: 8.0 Hz), 6.33 (1H; s; CH), 3.34 (3H; s; CH₃). IR; cm⁻¹ 3175 (NH), 1683 (C=O). ESI-MS (m/z); 478 [M+K]⁺, 462 [M+Na]⁺, 440 [M+H]⁺. Anal. Calcd. for C₂₅H₂₁N₅OS.1/2 H₂O: C, 66.94; H, 4.94; N, 15.61; S, 7.15. Found: C, 67.13; H, 4.64; N, 15.69; S, 7.28.

5-(4-Chlorobenzylidene)-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 9

43% yield, mp 163-4 °C. ¹H NMR (DMSO-d₆, 400 MHz); δ 9.29 (1H; s; triazole), 8.47 (1H; s; NH), 8.22 (1H; s; triazole), 7.88 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.65 (2H; d; Ar-H₃" and H₅"', *J*: 8.4 Hz), 7.59 (2H; d; Ar-H₃" and H₅"', *J*: 8.4 Hz), 7.51 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.48 (1H; s; CH=), 7.15 (2H; t; Ar-H₃' and H₅''), 6.75 (1H; t; Ar-H₄''), 6.65 (2H; d; Ar-H₂' and H₆'', *J*: 7.2 Hz), 6.35 (1H; s; CH). IR; cm⁻¹ 3268 (NH), 1676 (C=O). ESI-MS (m/z); 500 [M+K+2]⁺, 482 [M+Na+2]⁺. Anal. Calcd. for C₂₄H₁₈ClN₅OS.1/2 H₂O: C, 61.47; H, 4.08; N, 14.93; S, 6.84. Found: C, 61.94; H, 3.99; N, 15.22; S, 6.82.

5-Benzylidene-3-(phenylamino)-2-[4-(1H-

imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 10

41% yield, mp 189-90 °C. ¹H NMR (DMSO-d₆, 400 MHz); δ 8.48 (1H; s; NH), 8.26 (1H; s; imidazole), 7.74 (1H; s; imidazole), 7.68 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.57-7.45 (7H; m; CH=, Ar-H₂"', H₃"', H₅"', H₆"', H₃" and H₅"'), 7.36 (1H; t; Ar-H₄"'), 7.18 (2H; t; Ar-H₃' and H₅''), 7.09 (1H; s; imidazole), 6.76 (1H; t; Ar-H₄''), 6.66 (2H; d; Ar-H₂' and H₆'', *J*: 8.0 Hz), 6.33 (1H; s; CH). IR; cm⁻¹ 3288 (NH), 1698 (C=O). ESI-MS (m/z); 447 [M+Na]⁺, 425 [M+H]⁺. Anal. Calcd. for C₂₅H₂₀N₄OS: C, 70.73; H, 4.75; N, 13.20; S, 7.55. Found: C, 70.67; H, 4.99; N, 13.72; S, 7.43.

5-(4-Bromobenzylidene)-3-(phenylamino)-2-[4-(1H-imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 11

61% yield, mp 223-4 °C. ¹H NMR (DMSO-d₆, 400 MHz); δ 8.62 (1H; s; NH), 8.53 (1H; s; imidazole), 7.89 (1H; s; imidazole), 7.74 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.68 (2H; d; Ar-H₃" and H₅"', *J*: 8.4 Hz), 7.59 (2H; d; Ar-H₃" and H₅"', *J*: 8.8 Hz), 7.53 (2H; d; Ar-H₂" and H₆"', *J*: 9.2 Hz), 7.51 (1H; s; CH=), 7.31 (1H; s; imidazole), 7.18 (2H; t; Ar-H₃' and H₅''), 6.78 (1H; t; Ar-H₄''), 6.68 (2H; d; Ar-H₂' and H₆'', *J*: 8.0 Hz), 6.38 (1H; s; CH). IR; cm⁻¹ 3266 (NH), 1696 (C=O). ESI-MS (m/z); 527 [M+Na+2]⁺, 505 [M+H+2]⁺. Anal. Calcd. for C₂₅H₁₉BrN₄OS.3 H₂O: C, 53.86; H, 4.52; N, 10.05; S, 5.75. Found: C, 54.00; H, 4.12; N, 10.43; S, 5.85.

5-(4-Methylbenzylidene)-3-(phenylamino)-2-[4-(1H-imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 12

47% yield, mp 215-6 °C. ¹H NMR (DMSO-d₆, 400 MHz); δ 8.47 (1H; s; NH), 8.23 (1H; s; imidazole), 7.75 (1H; s; imidazole), 7.70 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.55 (2H; d; Ar-H₃" and H₅"', *J*: 8.4 Hz), 7.49 (1H; s; CH=), 7.47 (2H; d; Ar-H₃" and H₅"', *J*: 8.0 Hz), 7.29 (2H; d; Ar-H₂" and H₆"', *J*: 8.4 Hz), 7.18 (2H; t; Ar-H₃' and H₅''), 7.11 (1H; s; imidazole), 6.77 (1H; t; Ar-H₄''), 6.68 (2H; d; Ar-H₂' and H₆'', *J*: 8.0 Hz), 6.32 (1H; s; CH), 3.34 (3H; s; CH₃). IR; cm⁻¹ 3288 (NH), 1695 (C=O). ESI-MS (m/z); 477 [M+K]⁺, 439 [M+H]⁺. Anal. Calcd. for C₂₆H₂₂N₄OS.2 H₂O: C, 65.80; H, 5.52; N, 11.81; S, 6.76. Found: C, 65.25; H, 5.21; N, 11.73; S, 6.74.

5-(4-Chlorobenzylidene)-3-(phenylamino)-2-[4-(1H-imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 13

53% yield, mp 217-8 °C. ¹H NMR (DMSO-d₆, 400 MHz); δ 8.51 (1H; s; NH), 8.28 (1H; s; imidazole), 7.77 (1H; s; imidazole), 7.74 (2H; d; Ar-H₂' and H₆'', *J*: 8.4 Hz), 7.68 (2H; d; Ar-H₃' and H₅'', *J*: 8.4 Hz), 7.59 (2H; d; Ar-H₃' and H₅'', *J*: 8.8 Hz), 7.53 (2H; d; Ar-H₂' and H₆'', *J*: 9.2 Hz), 7.51 (1H; s; CH=), 7.18 (2H; t; Ar-H₃' and H₅'), 7.11 (1H; s; imidazole), 6.78 (1H; t; Ar-H₄'), 6.68 (2H; d; Ar-H₂' and H₆', *J*: 8.0 Hz), 6.36 (1H; s; CH). IR; cm⁻¹ 3268 (NH), 1697 (C=O). ESI-MS (m/z); 483 [M+Na+2]⁺, 461 [M+H+2]⁺. Anal. Calcd. for C₂₅H₁₉ClN₄OS.1/2 H₂O: C, 64.16; H, 4.31; N, 11.97; S, 6.85. Found: C, 64.27; H, 5.02; N, 11.21; S, 6.51.

Antimycobacterial Activity Assay

The target compounds were tested for their antimycobacterial activity *in vitro* against *M. tuberculosis* H₃₇R_v using the microplate alamar blue assay (MABA) method (27) in duplicate. Isoniazid, rifampin, ethambutol and ciprofloxacin were used as positive and DMSO as negative control. Compound stock solutions were prepared in DMSO. Sterile deionized water (200 μL) was added to all outer-perimeter wells of sterile 96-well plates to minimize evaporation of the medium in the test wells during incubation. The wells received 100 μL of Middlebrook 7H9GC broth and two fold serial dilutions of the target compounds/positive controls were prepared in a volume of 100 μL directly on the plate. 100 μL of *MTB* inoculum was added to the wells. The plates were sealed with parafilm and were incubated at 37 °C for five days. 50 μL of a freshly prepared 1:1 mixture of Alamar Blue (Accumed International, Westlake, Ohio) reagent and 10% Tween 80 was added to the plates and incubated at 37 °C for 24 h. A blue colour in the well was interpreted as no growth, and a pink colour was scored as growth. The MIC was determined as the lowest drug concentration which prevented a colour change from blue to pink. MICs of the compounds were reported in Table 1.

Conflict of Interest

We declare that we have no conflict of interest

with respect to this study.

Results and Discussion

Chemistry

The starting compounds, 4-(1*H*-1,2,4-triazol/imidazol-1-yl)benzaldehydes 1a-b were synthesized in accordance with the method described in the literature (26). The intermediate compounds, *Schiff* bases and hydrazones (2a-b and 3a-b), were obtained by condensation of 1a-b with anilin or phenylhydrazine respectively. Reaction of 2a-b and 3a-b with mercaptoacetic acid yielded the thiazolidin-4-ones 4a-b and 5a-b (Figure 1). Compounds 6-13 were gained by treatment of 5a-b with appropriate benzaldehydes according to *Knoevenagel* condensation as outlined in Figure 2. The structures of the target compounds (4a-b, 5a-b and 6-13) were confirmed by IR, ¹H NMR, mass spectrometry and elemental analysis.

In the IR spectra of compound 4a-b and 5a-b, the presence of the C=O stretching bands at around 1680 cm⁻¹ indicated the thiazolidin-4-one ring closure. In the ¹H NMR spectra of these compounds, the signals of nonequivalence methylenic protons of the thiazolidin-4-one ring were observed as two doublets at around 4.0 ppm (H_A) and as doublet at around 3.9 ppm (H_B) because of geminal (*J*_{AB} of 15.6 Hz) and long range coupling (~*J*_{Ax} of 1.6 Hz) with C₂ proton. Furthermore, the signal of the C₂ proton of the thiazolidin-4-one ring was seen as singlet or doublet at around 6.0 ppm. In the ¹H NMR spectra of 6-13, disappearance of the signals of methylenic protons and formation of a new signal at around 7.5 ppm proved benzylidene substitution to the thiazolidin-4-one ring. In the mass spectra, all compounds displayed molecular ion peaks which confirmed their molecular weight.

Antimycobacterial Activity

The target compounds (4a-b, 5a-b and 6-13) were evaluated for their antimycobacterial activity *in-vitro* against *Mycobacterium tuberculosis* H₃₇R_v using the microplate alamar blue assay method (27) in duplicate. The results of the antimycobacterial activity (MIC values) were reported in Table 1.

When Table 1. were examined, it was seen that introduction of phenylamino group (5a with MIC of 74.18 μM and 5b with MIC of 37.20 μM) instead of phenyl group (4a with MIC of 77.64 μM and 4b with MIC of 155.76 μM) to 3th position of thiazolidin-4-one ring contributed to the activity, although this contribution was very limited for triazole substituted derivatives.

These results led us to focus on 3-(phenylamino)-1,3-thiazolidin-4-ones. As a continuation of our study, we condensed several benzaldehydes to obtain 5-(substitutedbenzylidene)-3-(phenylamino)-1,3-thiazolidin-4-ones (6-13). When we compared the activity results of 5a and 5b with 6-9 and 10-13 respectively, it was observed that benzylidene substitution to the 3-(phenylamino)-1,3-thiazolidin-4-ones enhanced the activity (except 11). However 12 (MIC: 14.27 μM) was the most active derivative in this series, introducing the substituents at the 4th position of the benzylidene ring decreased the activity in generally. According to the activity results of 6 and 10 (with MIC of 14.70 and 14.74 μM respectively), it can be assumed that non-substitutedbenzylidene structure is a favorable moiety for the activity. Comparing the compounds bearing triazole moiety (6-9) with that of imidazole analogues (10-13), it was seen that the type of the azole ring did not cause any remarkable difference on the activity except methyl substituted derivatives (8 with MIC of 56.94 μM and 12 with MIC of 14.74 μM). Furthermore, none of the compounds in the series were found as active as standard compounds (Table 1).

In summary, a series of novel thiazolidin-4-one derivatives 4a-b, 5a-b and 6-13 were designed, synthesized to evaluate their antimycobacterial activity. Among the target compounds, 6, 10 and 12 were found as most active compounds in the series. It was seen that both phenylamino and benzylidene substitutions on thiazolidin-4-one ring caused an improvement in the antimycobacterial activity.

References

- (1) World Health Organization Global tuberculosis report, http://www.who.int/tb/publications/global_report/en/
- (2) Huebner RE and Castro KG. The changing face of tuberculosis. *Annu. Rev. Med.* (1995) 46: 47-55.
- (3) Datta M, Radhamani MP, Selvaraj R, Paramasivan CN, Gopalan BN, Sudeendra CR and Prabhakar R. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. *Tuber. Lung Dis.* (1993) 74: 180-6.
- (4) Forget EJ and Menzies D. Adverse reactions to first-line antituberculosis drugs. *Expert Opin. Drug Saf.* (2006) 5: 231-49.
- (5) Grundy WE, Whitman AL, Rdzok EG, Rdzok EJ, Hanes ME and Sylvester JC. Actithiazic acid. 1. Microbiological studies. *Antibiot. Chemother.* (1952) 2: 399-408.
- (6) Kucukguzel SG, Oruc EE, Rollas S, Sahin F and Ozbek A. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. *Eur. J. Med. Chem.* (2002) 37: 197-206.
- (7) Aridoss G, Amirthaganesan S, Kim MS, Kim JT and Jeong YT. Synthesis, spectral and biological evaluation of some new thiazolidinones and thiazoles based on t-3-alkyl-r-2,c-6-diarylpiperidin-4-ones. *Eur. J. Med. Chem.* (2009) 44: 4199-4210.
- (8) de Aquino TM, Liesen AP, da Silva REA, Lima VT, Carvalho CS, de Faria AR, de Araújo JM, de Lima JG, Alves AJ, de Melo EJT and Góes AJS. Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazone]-4-oxo-3-phenyl-5-thiazolidineacetic acids. *Bioorg. Med. Chem.* (2008) 16: 446-56.
- (9) Jaju S, Palkar M, Maddi V, Ronad P, Mamledesai S, Satyanarayana D and Ghatole M. Synthesis and antimycobacterial activity of a novel series of isonicotinylhydrazide derivatives. *Arch. Pharm.* (2009) 342: 723-31.
- (10) Srivastava T, Gaikwad AK, Haq W, Sinha S and Katti SB. Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents. *Arkivoc* (2005): 120-30
- (11) Gupta P, Hameed S and Jain R. Ring-substituted imidazoles as a new class of anti-tuberculosis agents. *Eur. J. Med. Chem.* (2004) 39: 805-814.
- (12) Khan A, Sarkar S and Sarkar D. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. *Int. J. Antimicrob. Agents* (2008) 32: 40-5.
- (13) Li X, Manjunatha UH, Goodwin MB, Knox JE, Lipinski CA, Keller TH, Barry CE 3rd and Dowd CS. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo [2,1-b][1,3]oxazines, analogues of PA-824. *Bioorg. Med. Chem. Lett.* (2008) 18: 2256-62.
- (14) Pandey J, Tiwari VK, Verma SS, Chaturvedi V, (2012).

- Bhatnagar S, Sinha S, Gaikwad AN and Tripathi RP. Synthesis and antitubercular screening of imidazole derivatives. *Eur. J. Med. Chem.* (2009) 44: 3350-5.
- (15) Wilkinson BL, Bornaghi LF, Wright AD, Houston TA and Poulsen SA. Anti-mycobacterial activity of a bis-sulfonamide. *Bioorg. Med. Chem. Lett.* (2007) 17 (5): 1355-7.
- (16) Gill C, Jadhav G, Shaikh M, Kale R, Ghawalkar A, Nagargoje D and Shiradkar M. Clubbed [1,2,3] triazoles by fluorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis. *Bioorg. Med. Chem. Lett.* (2008) 18: 6244-7.
- (17) Castagnolo D, Radi M, Dessi F, Manetti F, Saddi M, Meleddu R, De Logu A and Botta M. Synthesis and biological evaluation of new enantiomerically pureazole derivatives as inhibitors of Mycobacterium tuberculosis. *Bioorg. Med. Chem. Lett.* (2009) 19: 2203-5.
- (18) Turan-Zitouni G, Özdemir A, Asim Kaplancikli Z, Benkli K, Chevallet P and Akalin G. Synthesis and antituberculosis activity of new thiazolylhydrazone derivatives. *Eur. J. Med. Chem.* (2008) 43: 981-5.
- (19) Mallikarjuna BP, Sastry BS, Suresh Kumar GV, Rajendraprasad Y, Chandrashekar SM and Sathisha K. Synthesis of new 4-isopropylthiazole hydrazide analogs and some derived clubbed triazole, oxadiazole ring systems--a novel class of potential antibacterial, antifungal and antitubercular agents. *Eur. J. Med. Chem.* (2009) 44: 4739-46.
- (20) Mai A, Artico M, Esposito M, Ragno R, Sbardella G and Massa S. Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. *Farmaco* (2003) 58: 231-41.
- (21) Mamolo MG, Zampieri D, Falagiani V, Vio L, Fermeiglia M, Ferrone M, Pricl S, Banfi E and Scialino G. Antifungal and antimycobacterial activity of new N-1-[1-aryl-2-(1H-imidazol-1-yl and 1H-1,2,4-triazol-1-yl)-ethylidene]-pyridine-2-carboxamidrazone derivatives: a combined experimental and computational approach. *Arkivoc* (2004): 231-50.
- (22) Castagnolo D, Manetti F, Radi M, Bechi B, Pagano M, De Logu A, Meleddu R, Saddi M and Botta M. Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones. *Bioorg. Med. Chem.* (2009) 17: 5716-21.
- (23) Tangallapally RP, Sun D, Rakesh, Budha N, Lee RE, Lenaerts AJ and Meibohm B. Discovery of novel isoxazolines as anti-tuberculosis agents. *Bioorg. Med. Chem. Lett.* (2007) 17: 6638-42.
- (24) Mamolo MG, Zampieri D, Vio L, Fermeiglia M, Ferrone M, Pricl S, Scialino G and Banfi E. Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations. *Bioorg. Med. Chem.* (2005) 13: 3797-809.
- (25) Jain AK, Vaidya A, Ravichandran V, Kashaw SK and Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: A review. *Bioorg. Med. Chem.* (2012) 20: 3378-95.
- (26) Mečiarová M, Toma Š, Magdolen P. Ultrasound effect on the aromatic nucleophilic substitution reactions on some haloarenes. *Ultrason. Sonochem.* (2003) 10: 265-70.
- (27) Collins LA and Franzblau SG. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. *Antimicrob. Agents Ch.* (1997) 41: 1004-9.